Scientific Advisory Board
Strategic Advisor, MD, PhD Kapil Dhingra
Dr. Dhingra offers a long international career in the oncology field having held executive positions in pharmaceutical companies such as Hoffmann-La Roche and Eli Lilly whilst sitting in several renowned cancer institute faculties in the US. Dr. Dhingra is Board-certified in Internal Medicine and Medical Oncology and currently Chairman of the Board of Exosome Diagnostics and member of the BoD of Advanced Accelerator Applications, Five Prime and Autolus. He has previously served on the Boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, and Epitherapeutics. In addition, Dr. Dhingra is an advisor to several biotechnology and pharmaceutical companies and healthcare organizations through his own company KAPital Consulting LLC, a member of the NCI Experimental Therapeutics Panel and a member of the New Drug Advisory Committee of the EORTC.
Strategic Advisor, MD, PhD Samir N. Khleif
Dr. Samir N. Khleif is an internationally recognized cancer physician, scientist, administrator and educator whose diverse interests and experiences have allowed him to develop an unparalleled skillset. His medical background and research experience - which include high-profile posts at the National Cancer Institute (NCI), the King Hussein Cancer Centre, the King Hussein Institute for Biotechnology and Cancer and the Georgia Cancer Center at Augusta University - has focused primarily on translational research and trials, with a focus on immune therapy and cancer vaccine programs. His work at NCI, for example, led to the first clinical trials in antigen-directed cancer vaccines. As an administrator, he has a proven track record for not only leading and managing complex cancer-focused organizations, but establishing them as well. He served as Director General and CEO of the King Hussein Cancer Centre in Jordan, transforming the facility into a ‘US-style’ comprehensive cancer center. He also led the effort to establish and build the King Hussein Institute for Biotechnology and Cancer. Dr. Khleif’s success in program development, on a both national and international level, is well documented, as is his ability to establish and develop strong partnerships. His work with government agencies, the pharmaceutical community and aligned institutions regularly leads to groundbreaking research and care. As the Director of the Georgia Cancer Center, Dr. Khleif has attracted world-class physicians and researchers in fields such as neuro-oncology, radiation oncology, bone marrow transplant and breast cancer. He has also been instrumental in establishing a patient- and family-focused multidisciplinary team approach to clinical care.
Founder, Clinical Advisor, Professor, MD, PhD Inge Marie Svane
Professor and Director of CCIT (Center for Cancer Immune Therapy at Herlev University Hospital. IMS has extensive experience in clinical translation of immune therapies and is an advisor for several large pharma companies. Currently running a phase III trial
Strategic Advisor, MD, PhD Vincenzo Bronte
Prof. Vincenzo Bronte, M.D., started his research career at University of Padova (Italy). Then he moved to the Surgery Branch of the National Institutes of Health (NIH, Bethesda, USA), where he was actively involved in cancer immunology and immunotherapy researches. During these years, Prof. Bronte was among the pioneers to define and characterize myeloid cells with immune regulatory functions that are now called myeloid-derived suppressor cells (MDSC). At the Immunology Section of Verona University, where he is currently heading the immunology branch of Department of Medicine, Prof. Bronte is focusing on the development of innovative MDSC-targeting strategies by either conventional chemotherapy or innovative approaches, as well as defining novel markers for human MDSC. In the last 10 years, Prof. Bronte participated as invited speaker in more than 120 international/national congresses. He has received several scientific awards, such as the Prize "Guido Venosta" for oncology researchers with the following motivation: “For his pioneering studies in the Immunology field, crucial for the development of successful anti-tumoral immunotherapies” by the Italian Foundation for Cancer Research (FIRC) and consigned by the President of the Italian Republic. He is reviewer and member of different Commissions of Trust and Advisory Boards for European and International funding agencies and Companies.
Strategic Advisor, Msc, PhD Jerome Galon
Dr Jerome Galon is a Research Director at Inserm and Head of the Laboratory of Integrative Cancer Immunology in Paris, and he is best known internationally for his contribution to cancer immunology fields by implementing Immunoscore® as a new approach to cancer classification. He is a co-founder of halio dx (www.haliodx.com), established in 2014.
Strategic Advisor, MBA, Kathleen Sereda Glaub
Ms. Glaub has over 30 years in executive-level corporate development, financing and company-building for leading life science and technology innovation-based companies. She has a strong track record in strategic decision making enabling and re-positioning companies to transform business value. Most recently, as Chief Executive Officer of Afferent Pharmaceuticals from 2014-2016, Ms. Glaub led the company’s development of it lead molecule, AF-219/MK-7264, through a full complement of mid-stage clinical trials to Phase 3 readiness as a novel treatment for chronic cough, and ultimately, to the sale of the company to Merck in 2016 for $1.25 billion, including $500 million upfront. She also raised $80 million additional private funding, including a crossover round. She had joined the Afferent Board in 2013. Prior to Afferent, Ms. Glaub co-led Plexxikon Inc. as President for 12 years, until May 2013. In this role, she led the business and financing strategy for the company, including negotiating six partnerships generating over several hundred million in non-equity funding, and led the company’s buyout by Daiichi Sankyo for nearly $1 billion cash in 2011. She also was instrumental in Plexxikon’s advancement of multiple novel molecules to the clinic, as well as advancement of ZelborafTM, a targeted treatment for melanoma, along with its companion diagnostic to market approval in 2011. Prior experience also included positions as SVP & CFO of Cell Genesys, Treasurer of Genentech, and various finance and treasury roles with Intel Corporation. Ms. Glaub received her MBA from Northwestern University, and her BA from the University of California, Berkeley.